secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001711
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer
--------------------------------------------------------------------------------

- Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.
- Mack resigns as CFO; receives $500K base salary, 50% target bonus, and option for 271,325 shares at $2.44.
- Gianluca Fuggetta, VP of Finance, becomes SVP Finance and Principal Financial Officer; base salary CHF 200K.
- Mack brings 25+ years biotech experience; Fuggetta previously served as interim Principal Financial Officer in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/0001104659-25-001711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925001711/tm252048d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer